In this audio segment from our recent Insight Matters publication, our experts explore the new frontier of the weight loss industry.
Read the full report here: Insight Matters report, Spring 2025 | TrinityBridge
The obesity drugs sector, forecast to be worth somewhere in the region of $150-200bn per year by 2035, has garnered an ever-increasing amount of attention in recent years. And as our understanding of the link between obesity and other health conditions has increased, so too has the demand for treatment using these drugs. James Tulloch met with Jon Kirk to assess this fascinating and fast-evolving area and discuss how both the growing demand and the ongoing evolution of these drugs might shape the market in the future.
This podcast is brought to you by TrinityBridge – trinitybridge.com – and features James Tulloch, Senior Investment Specialist, in conversation with Jon Kirk, Senior Equity Analyst.
We’ve created this podcast to set out possible approaches. Please do not view it as financial advice, or its content as investment recommendations. Just because an investment or an investment strategy has performed well in the past, does not mean it will continue to do so. Our predictions are based on information that is currently available, however events and markets can and do change rapidly.